Literature DB >> 25895008

Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review.

Emily K Wright1, Michael A Kamm.   

Abstract

Crohn's disease is associated with substantially impaired health-related quality of life (HRQoL). Even in the absence of active disease, patients with Crohn's disease report lower HRQoL, poorer function, and greater concerns, than those without disease. Achievement of disease remission in Crohn's disease, whether by pharmacological or surgical means, is associated with improved HRQoL, although the durability of the improvement seen after intestinal resection is uncertain because of the high rate of postoperative disease recurrence. This review focuses on the available literature on HRQoL in patients with Crohn's disease with an emphasis on the effects of intestinal resection and immunomodulatory therapy.

Entities:  

Mesh:

Year:  2015        PMID: 25895008     DOI: 10.1097/MIB.0000000000000271

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  16 in total

1.  Linkage between genotype and immunological phenotype in Crohn's disease.

Authors:  Gwenny M Fuhler; Kaushal Parikh; C Janneke van der Woude; Maikel P Peppelenbosch
Journal:  Ann Transl Med       Date:  2015-09

Review 2.  Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.

Authors:  Fernando Bermejo; Iván Guerra; Alicia Algaba; Antonio López-Sanromán
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

3.  Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease.

Authors:  Éanna J Ryan; Gabriel Orsi; Michael R Boland; Adeel Zafar Syed; Ben Creavin; Michael E Kelly; Kieran Sheahan; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; Des C Winter; James M O'Riordan
Journal:  Int J Colorectal Dis       Date:  2020-01-09       Impact factor: 2.571

Review 4.  Role of Fecal Diversion in Complex Crohn's Disease.

Authors:  John P Burke
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

5.  Disutility Study for Adult Patients with Moderate to Severe Crohn's Disease.

Authors:  Melany Worbes-Cerezo; Beenish Nafees; Andrew Lloyd; Katy Gallop; Imran Ladha; Cicely Kerr
Journal:  J Health Econ Outcomes Res       Date:  2019-03-26

6.  Strictureplasty versus bowel resection for the surgical management of fibrostenotic Crohn's disease: a systematic review and meta-analysis.

Authors:  Waqas T Butt; Éanna J Ryan; Michael R Boland; Eilis M McCarthy; Joseph Omorogbe; Karl Hazel; Gary A Bass; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; James M O'Riordan
Journal:  Int J Colorectal Dis       Date:  2020-02-11       Impact factor: 2.571

Review 7.  A Multi-Disciplinary Approach to Perianal Fistulizing Crohn's Disease.

Authors:  Jacob Wiseman; Tanya Chawla; Frederic Morin; Anthony de Buck van Overstraeten; Adam V Weizman
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

Review 8.  Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab.

Authors:  Jill Mv Petkau; Bertus Eksteen
Journal:  Biologics       Date:  2016-03-09

Review 9.  A systematic review of disease-related stigmatization in patients living with inflammatory bowel disease.

Authors:  Tiffany H Taft; Laurie Keefer
Journal:  Clin Exp Gastroenterol       Date:  2016-03-07

Review 10.  Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions.

Authors:  Mark G Ward; Miles P Sparrow; Xavier Roblin
Journal:  Therap Adv Gastroenterol       Date:  2018-05-08       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.